Andere talen Arbutus Biopharma Corporation

Aandelen

ABUS

CA03879J1003

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,73 ^USD	+0,37%		+0,37%	+9,20%

05/04	Arbutus Biopharma verkrijgt gunstig vonnis in rechtszaak over Moderna-patenten	MT
04/04	Moderna krijgt tegenslag in rechtszaak tegen Arbutus	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	18/04
Arbutus Biopharma : Corporate Presentation - April 2024	15/04
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05/04
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	04/04
Moderna Suffers Setback in Lawsuit by Arbutus	04/04
Moderna shares fall after judge sides with Arbutus in patent fight	03/04
Arbutus to Participate in Two Upcoming Investor Conferences	08/03
Arbutus to Participate in Two Upcoming Investor Conferences	08/03
Arbutus Biopharma Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	01/03
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29/02
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29/02
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update	15/02
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08/01
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08/01
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	08/01
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09/11
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®	09/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arbutus Biopharma Corporation

Aandelen

ABUS

CA03879J1003

Andere talen

Filters